NCT04056988View on ClinicalTrials.gov

tSCI Contrast Enhanced Ultrasound Study

PHASE4CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

November 20, 2023

Study Completion Date

November 20, 2023

Conditions
Acute Spinal Cord Injury
Interventions
DRUG

Perflutren Lipid Microsphere

Perflutren lipid microsphere preparation is an ultrasound contrast agent. Ultrasound contrast agents are used to help provide a clear picture during ultrasound.

Trial Locations (1)

98104

Harborview Medical Center, Seattle

All Listed Sponsors
lead

University of Washington

OTHER

NCT04056988 - tSCI Contrast Enhanced Ultrasound Study | Biotech Hunter | Biotech Hunter